HIV/AIDS Drug Development
Tricyclic HIV integrase inhibitor has increased potency and solubility
Published in AIDS Weekly, October 2nd, 2006
"A novel class of tricyclic HIV integrase inhibitors were designed based on conformational analysis of 1,6-naphthyridine carboxamide compound L-870810 and docking the designed inhibitor into the active site of our integrase enzyme model," scientists in the United States report.
According to H.L. Jin and colleagues at Gilead Sciences Inc., "The efficient syntheses of pyrroloquinoline tricyclic analogs are described."
"The SAR studies resulted in the identification of a lead compound that is more potent and more soluble than L-870810," concluded...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-10-02)
More Articles from AIDS Weekly
- HIV/AIDS HAART
Fosamprenavir-ritonavir similar in safety and efficacy as lopinavir-ritonavir in HIV/AIDS - HIV/AIDS Pathogenesis
HIV-1 integration in untreated infection occurs preferentially within genes - HIV/AIDS Prognostics
Serum albumin predicts severity of HIV infection and monitors response to HAART - HIV/AIDS Therapy
Virological response, not mortality improved in first decade of HAART use in HIV/AIDS - Apoptosis
Azidothymidine in adult T cell leukemia/lymphoma patients results in tumor cell death - Blood Safety
Precautions necessary during hand surgery on patients at high-risk for blood-borne viruses - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
